The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non ‐small cell lung cancer

ConclusionsPDW might act as an independent risk factor to predict progression and prognosis. Preoperative PDW combined with the TNM staging system showed a better ability to assess the prognosis of NSCLC patients.Key points Our study focused on the prognostic value of preoperative PDW in 750 patients with NSCLC. We also analyzed preoperative PDW in different stages and histological subtypes systematically. A model built by preoperative PDW combined with the TNM staging system had a better prognostic ability. LRT was used to calculate values of the goodness of fit between the model and the TNM staging system.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

AbstractBackgroundSubxiphoid uniportal video ‐assisted thoracoscopic surgery (SVATS) is more technically challenging than intercostal uniportal video‐assisted thoracoscopic surgery (UVATS), especially in more complex procedures such as segmentectomy. We therefore aimed to investigate the worthiness of undertaking the more demanding subxiph oid approach in patients who had undergone anatomical segmentectomy for stage IA non‐small cell lung cancer (NSCLC).MethodsA total of 491 patients were included in our study who had undergone anatomical segmentectomy for stage IA non ‐small cell lung cancer from September 2014 to...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
The immunotherapy is now approved for use in patients with small cell lung cancer (SCLC); it was already approved for non-small cell lung cancer (NSCLC).FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Contributors : Ivan Martinez ; Tayvia BrownmillerSeries Type : Expression profiling by arrayOrganism : Homo sapiensNumerous studies have implicated changes in the Y chromosome in male cancers, however few have investigated the biological importance of Y chromosome non-coding RNAs. Here, we demonstrate a group of Y chromosome-expressed long non-coding RNAs (lncRNAs) involved in male non-small cell lung cancer (NSCLC) radiation sensitivity. Radiosensitive male NSCLC cell lines demonstrated a dose-dependent induction of linc-SPRY3-2/3/4 following irradiation, not observed in radioresistant male NSCLC cell lines. Cytogenetics ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Condition:   IIIA Stage Non-small Cell Lung Cancer Intervention:   Drug: Sintilimab Injection Sponsor:   First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Bone Metastatic Non-small Cell Lung Cancer Interventions:   Drug: AL2846;   Drug: Zoledronic Acid Injection Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Stage III Non-small-cell Lung Cancer Interventions:   Drug: TQB2450;   Drug: Anlotinib;   Drug: TQB2450(blank);   Drug: Anlotinib(blank) Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   IIIA Stage Non-small Cell Lung Cancer Intervention:   Drug: Sintilimab Injection Sponsor:   First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Bone Metastatic Non-small Cell Lung Cancer Interventions:   Drug: AL2846;   Drug: Zoledronic Acid Injection Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Stage III Non-small-cell Lung Cancer Interventions:   Drug: TQB2450;   Drug: Anlotinib;   Drug: TQB2450(blank);   Drug: Anlotinib(blank) Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study